Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AMB 051

Next Previous
Search
Drug Profile

AMB 051

Alternative Names: AMB 053; AMB-051; AMB-055; AMB-05X; AMG-820

Latest Information Update: 28 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amgen
  • Developer Amgen; AmMax Bio; LifeMax Laboratories
  • Class Antibodies; Antifibrotics; Antineoplastics; Eye disorder therapies; Immunotherapies; Monoclonal antibodies; Urologics
  • Mechanism of Action Macrophage colony-stimulating factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Giant cell tumour of tendon sheath; Idiopathic pulmonary fibrosis
  • Phase I/II Solid tumours
  • Preclinical Diabetic macular oedema; Wet age-related macular degeneration
  • No development reported Autosomal recessive polycystic kidney disease; Unspecified

Most Recent Events

  • 28 Apr 2025 No recent reports of development identified for preclinical development in Autosomal-recessive-polycystic-kidney-disease in USA
  • 28 Apr 2025 No recent reports of development identified for preclinical development in Unspecified in USA
  • 01 Oct 2024 M.D. Anderson Cancer Center plans a phase II trial for Colorectal cancer in USA (IV) in February 2025 (NCT06617858)

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top